Drug toxicity, HIV progression, or comorbidity of aging: Does tipranavir use increase the risk of intracranial hemorrhage?

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1226-1230

  Justice, Amy C ^a,b   Zingmond, David S ^c   Gordon, Kirsha S ^a,b   Fultz, Shawn L ^a   Goulet, Joseph L ^a,b   King Jr , Joseph T ^a,b   Bravata, Dawn M ^a,b   Valdez, Hernan ^d   Kraft, Michael ^e   Mattocks, Kristin M ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE; TIPRANAVIR; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGING; ALCOHOL ABUSE; ALGORITHM; ARTICLE; BIVARIATE ANALYSIS; BRAIN HEMORRHAGE; CHI SQUARE TEST; COCAINE DEPENDENCE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DEPENDENCE; DRUG EXPOSURE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; INFECTION RATE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; POISSON DISTRIBUTION; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CALIFORNIA; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; HIV INFECTIONS; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MEDICAID; MIDDLE AGED; PYRIDINES; PYRONES; RISK FACTORS; UNITED STATES; VETERANS;

EID: 53349128051     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592302     Document Type: Article

References (15)

1. US Food and Drug Administration. Important safety information: intracranial hemorrhage in patients receiving Aptivus (tipranavir) capsules. 30 June 2006. Available at: http://www.fda.gov/medwatch/safety/2006/Aptivus- tipranavir_DHCP.pdf. Accessed 15 January 2008.
2. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999; 30:736-43.
3. Cole JW, Pinto AN, Hebel JR, et al. Acquired immunodeficiency syndrome and the risk of stroke. Stroke 2004; 35:51-6.
4. Nuss R, Soucie JM, Evatt B. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol 2001; 68:37-42.
5. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130:1326-33.
6. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006; 44(Suppl 2):S52-60.
7. Bisson G, Gross R, Miller V, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003; 17:2407-17.
8. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006; 44(Suppl 2):S25-30.
9. Zingmond DS, Ettner SL, Cunningham WE. The impact of managed care on access to highly active antiretroviral therapy and on outcomes among HIV-infected Medicaid beneficiaries. Med Care Res Rev 2007; 64:66-82.
10. Wright SM, Petersen LA, Lamkin RP, Daley J. Increasing use of Medicare services by veterans with acute myocardial infarction. Med Care 1999; 37:529-37.
11. Fleming C, Fisher ES, Chang C-H, Bubolz TA, Malenka DJ. Studying outcomes and hospital utilization in the elderly: the advantages of a merged data base for Medicare and Veterans Affairs hospitals. Med Care 1992; 30:377-91.
12. Kokotailo RA, Hill MD. Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke 2005; 36:1776-81.
13. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127:757-63.
14. Hernan MA, Brumback BA, Robins JM. Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med 2002; 21:1689-709.
15. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60.